TNXP · CIK 1430306
What Tonix Pharmaceuticals Holding Corp. told the SEC could break it.
Tonix's disclosures center on supply, funding, and buyer dependencies. Some materials it needs for testing and finished product — including modified and unmodified pharmaceutical compounds — are available from only one supplier, so a single sole-source interruption could delay or halt manufacturing. It has run net losses and negative operating cash flows since inception and expects that to continue, funding itself partly through large at-the-market equity offerings (up to $400M) that create ongoing dilution. And its smallpox/mpox vaccine TNX-801 targets a market dominated by the government Special Reserve Fund — the sole medical-countermeasures buyer for the last decade, now annually appropriated and not keeping pace with stockpiling needs — leaving commercial success uncertain even with FDA licensure.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Sole-source suppliers/vendors for pharmaceutical compounds and finished productshigh
Some materials Tonix needs for preclinical/clinical testing and final product — including modified and unmodified pharmaceutical compounds and finished products — are available from only one supplier or vendor, so a single supplier's interruption could delay or halt manufacturing.
“Some of these materials are available from only one supplier or vendor. Any interruption in or termination of service by such sole source suppliers could result in a delay or interruption in manufacturing until we locate an alternative source of supply.”
SEC filing →As of 2026
Liquidity & debt
- Sustained net losses and negative operating cash flow, reliance on ATM equity salesmedium
Tonix has had net losses and negative operating cash flows since inception and expects these to continue, funding itself in part through large at-the-market equity offerings (up to $400M via AGP), creating ongoing dilution and financing risk despite newly launched commercial products.
“The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future.”
SEC filing →As of 2026
Regulatory & policy
- TNX-801 dependence on the government Special Reserve Fund / stockpile marketmedium
Tonix's smallpox/mpox vaccine TNX-801 targets a market dominated by the government Special Reserve Fund (SRF), the sole medical-countermeasures buyer for the last decade, which is now annually appropriated and has not kept pace with stockpiling needs — leaving commercial success uncertain even with FDA licensure.
“or SRF, has been the sole medical countermeasures market for the last decade. The SRF is now appropriated annually and has not kept pace with the need for purchasing products ready for stockpiling.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Upsher-Smith Laboratories
“We have assumed certain obligations of Upsher Smith, including the payment of quarterly royalty payments on annual net sales from the Business in the U.S. as follows: for Tosymra, 4% for net sales of $0 to $30 million, 7% of net sales of $30 to $75 million; 9% for net sales of $75 to $100 million; 12% for net sales of $100 to $150 million; and 15% for net sales greater than $150 million.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch